Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!
Triboo Gelecekteki Büyüme
Future kriter kontrolleri 4/6
Triboo is forecast to grow earnings and revenue by 171.5% and 18.4% per annum respectively while EPS is expected to grow by 169.4% per annum.
Anahtar bilgiler
171.5%
Kazanç büyüme oranı
169.4%
EPS büyüme oranı
Media kazanç büyümesi | 9.3% |
Gelir büyüme oranı | 18.4% |
Gelecekteki özkaynak getirisi | n/a |
Analist kapsamı | Low |
Son güncelleme | 19 Mar 2024 |
Gelecekteki son büyüme güncellemeleri
Recent updates
Capital Allocation Trends At Triboo (BIT:TB) Aren't Ideal
Sep 17The Returns On Capital At Triboo (BIT:TB) Don't Inspire Confidence
Nov 24Downgrade: What You Need To Know About The Latest Triboo S.p.A. (BIT:TB) Forecasts
Oct 11Here's Why Triboo (BIT:TB) Is Weighed Down By Its Debt Load
Oct 05Here's What To Make Of Triboo's (BIT:TB) Decelerating Rates Of Return
Jul 06The Triboo S.p.A. (BIT:TB) Analysts Have Been Trimming Their Sales Forecasts
Apr 14What Is Triboo S.p.A.'s (BIT:TB) Share Price Doing?
Mar 17Is Now The Time To Look At Buying Triboo S.p.A. (BIT:TB)?
Sep 24Triboo (BIT:TB) Has A Pretty Healthy Balance Sheet
May 19At €1.26, Is Triboo S.p.A. (BIT:TB) Worth Looking At Closely?
Mar 25Is Triboo (BIT:TB) Using Too Much Debt?
Sep 28At €1.45, Is Triboo S.p.A. (BIT:TB) Worth Looking At Closely?
Aug 31What Does Triboo S.p.A.'s (BIT:TB) Share Price Indicate?
May 17Triboo S.p.A. (BIT:TB) Investors Should Think About This Before Buying It For Its Dividend
Mar 19Here's What To Make Of Triboo's (BIT:TB) Returns On Capital
Jan 25Is It Too Late To Consider Buying Triboo S.p.A. (BIT:TB)?
Dec 02Kazanç ve Gelir Büyüme Tahminleri
Tarih | Gelir | Kazançlar | Serbest Nakit Akışı | Faaliyetlerden Nakit | Avg. Analist Sayısı |
---|---|---|---|---|---|
12/31/2025 | 92 | 1 | 4 | N/A | 1 |
12/31/2024 | 85 | 0 | 1 | N/A | 1 |
6/30/2024 | 68 | -5 | N/A | N/A | N/A |
3/31/2024 | 72 | -4 | N/A | N/A | N/A |
12/31/2023 | 76 | -3 | -4 | 2 | N/A |
6/30/2023 | 83 | -1 | -8 | -2 | N/A |
3/31/2023 | 87 | 0 | -9 | -2 | N/A |
12/31/2022 | 91 | 1 | -9 | -2 | N/A |
9/30/2022 | 94 | 1 | -3 | 3 | N/A |
6/30/2022 | 97 | 1 | 3 | 9 | N/A |
3/31/2022 | 96 | 2 | 6 | 13 | N/A |
12/31/2021 | 95 | 2 | 9 | 16 | N/A |
9/30/2021 | 92 | 2 | 9 | 15 | N/A |
6/30/2021 | 89 | 3 | 9 | 14 | N/A |
3/31/2021 | 85 | 2 | 7 | 12 | N/A |
12/31/2020 | 81 | 1 | 5 | 10 | N/A |
9/30/2020 | 79 | 0 | 0 | 6 | N/A |
6/30/2020 | 77 | -1 | -5 | 1 | N/A |
3/31/2020 | 77 | 0 | -3 | 6 | N/A |
12/31/2019 | 77 | 0 | 0 | 10 | N/A |
9/30/2019 | 75 | 0 | 0 | 12 | N/A |
6/30/2019 | 73 | 0 | 1 | 14 | N/A |
3/31/2019 | 70 | 1 | 1 | 13 | N/A |
12/31/2018 | 67 | 2 | 1 | 13 | N/A |
9/30/2018 | 66 | 2 | 1 | 12 | N/A |
6/30/2018 | 65 | 2 | 1 | 11 | N/A |
3/31/2018 | 65 | 1 | N/A | 9 | N/A |
12/31/2017 | 65 | 1 | N/A | 7 | N/A |
9/30/2017 | 65 | 2 | N/A | 9 | N/A |
6/30/2017 | 65 | 3 | N/A | 10 | N/A |
3/31/2017 | 65 | 3 | N/A | 10 | N/A |
12/31/2016 | 65 | 4 | N/A | 10 | N/A |
9/30/2016 | 57 | 3 | N/A | 8 | N/A |
6/30/2016 | 49 | 3 | N/A | 6 | N/A |
3/31/2016 | 41 | 3 | N/A | 6 | N/A |
12/31/2015 | 34 | 3 | N/A | 7 | N/A |
9/30/2015 | 32 | 3 | N/A | 6 | N/A |
6/30/2015 | 30 | 3 | N/A | 5 | N/A |
3/31/2015 | 29 | 2 | N/A | 4 | N/A |
12/31/2014 | 29 | 2 | N/A | 2 | N/A |
6/30/2014 | 25 | 2 | N/A | 4 | N/A |
3/31/2014 | 23 | 2 | N/A | 4 | N/A |
12/31/2013 | 21 | 2 | N/A | 5 | N/A |
Analist Gelecek Büyüme Tahminleri
Kazançlar ve Tasarruf Oranları: TB is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.4%).
Kazançlar ve Piyasa: TB is forecast to become profitable over the next 3 years, which is considered above average market growth.
Yüksek Büyüme Kazançları: TB is expected to become profitable in the next 3 years.
Gelir ve Pazar: TB's revenue (18.4% per year) is forecast to grow faster than the Italian market (3.9% per year).
Yüksek Büyüme Geliri: TB's revenue (18.4% per year) is forecast to grow slower than 20% per year.
Hisse Başına Kazanç Büyüme Tahminleri
Gelecekteki Özkaynak Getirisi
Gelecekteki ROE: Insufficient data to determine if TB's Return on Equity is forecast to be high in 3 years time